Cialis (Tadalafil) vs Vardenafil (Levitra/Staxyn): Real-World Evidence Comparison

How These Two Drugs Work

Both tadalafil and vardenafil block PDE5, the enzyme that degrades cyclic GMP in smooth-muscle cells of the corpus cavernosum. Higher cyclic GMP keeps the smooth muscle relaxed, allowing arterial inflow and penile rigidity in response to sexual stimulation. Neither drug produces erections without arousal. The FDA approved tadalafil in 2003 and vardenafil in 2003 as well, making both agents part of the same regulatory generation of PDE5 inhibitors. [1][2]

Selectivity Differences That Matter Clinically

Vardenafil is roughly 10-fold more potent than sildenafil at the PDE5 receptor and shows slightly greater selectivity for PDE5 over PDE6 (the retinal enzyme) compared with sildenafil, which may explain its lower rate of blue-tinge visual disturbance. [3] Tadalafil is selective for PDE5 over PDE6 as well, but it also inhibits PDE11, an enzyme expressed in skeletal muscle and the testes. The clinical significance of PDE11 inhibition remains debated; no reproductive toxicity signal has emerged in post-market surveillance. [4]

The Cyclic GMP Cascade in Practice

Sexual stimulation triggers nitric oxide release from penile endothelium. Nitric oxide activates guanylate cyclase, cyclic GMP rises, smooth muscle relaxes. PDE5 normally terminates this signal within minutes. By blocking PDE5, both drugs extend and amplify the natural erectile response rather than creating one from scratch. [5]

Pharmacokinetics: The Most Clinically Important Difference

The half-life gap between these two drugs drives almost every real-world prescribing decision. Tadalafil's mean half-life of 17.5 hours means that a single 20 mg dose produces detectable plasma concentrations for up to 36 hours, earning its colloquial label as "the weekend pill." [1] Vardenafil's half-life of 4 to 5 hours means the effective dosing window closes roughly 6 to 8 hours after ingestion. [2]

Tadalafil Daily Dosing

The 2.5 mg and 5 mg once-daily tadalafil formulations reach steady-state within 5 days and remove the need to time intercourse. [1] The FDA-approved label confirms that 5 mg once daily produced statistically significant improvements on the International Index of Erectile Function Erectile Function (IIEF-EF) domain compared with placebo across three phase-3 trials. [6] Men with lower urinary tract symptoms from benign prostatic hyperplasia benefit from the same 5 mg daily dose, giving tadalafil a dual indication that vardenafil does not carry. [7]

Vardenafil and the Staxyn Orally Disintegrating Tablet

Staxyn, the orally disintegrating tablet (ODT) formulation of vardenafil, dissolves on the tongue without water. Bioavailability of the ODT is approximately 21 percent higher than the film-coated tablet at the same nominal 10 mg dose, likely because buccal and esophageal mucosa absorb some drug before first-pass hepatic metabolism. [8] Men who dislike swallowing pills or who want faster onset in social situations sometimes prefer the ODT. The Staxyn label carries the same contraindications as Levitra; the two should not be used interchangeably on a milligram-for-milligram basis. [8]

Food and Alcohol Interactions

A high-fat meal reduces tadalafil's Cmax by roughly 30 percent but does not change overall AUC, so clinicians typically tell patients to take tadalafil with or without food. [1] Vardenafil's Cmax drops by 18 to 50 percent after a high-fat meal, making fasting or a light meal preferable for on-demand use. [2] Moderate alcohol (two standard drinks) does not produce clinically meaningful additive hypotension with either drug, but heavier consumption potentiates vasodilation and increases fall risk in older men. [9]

Efficacy: What the Key Trials Show

Brock et al. 2002 (Tadalafil)

Brock and colleagues published a key dose-response trial of tadalafil in the Journal of Urology (N = 179). Tadalafil 20 mg produced successful intercourse in 75 percent of attempts vs. 32 percent for placebo (P<0.001). The IIEF-EF domain score improved by 7.4 points from baseline with tadalafil 20 mg. [10] This dataset was among the earliest to confirm that the 36-hour window translated into real behavioral benefit: men reported feeling less rushed and less anxious about timing. [10]

Porst et al. 2003 (Vardenafil)

Porst and colleagues conducted a randomized, double-blind, placebo-controlled trial of vardenafil across multiple ED etiologies (N = 580). Vardenafil 20 mg improved the IIEF-EF domain score by 7.1 points from baseline vs. 1.7 points for placebo (P<0.001), and the per-attempt intercourse success rate reached 71 percent with the 20 mg dose. [11] Men with diabetes and men post-radical prostatectomy showed smaller absolute gains but still statistically significant responses. [11]

Direct Comparisons Are Rare

No large, industry-independent head-to-head randomized controlled trial has compared tadalafil directly against vardenafil on the IIEF-EF as a primary endpoint with adequate power. Most comparative data comes from network meta-analyses and cross-over observational studies. A 2021 Cochrane-style network meta-analysis of 82 trials (N = 29,768) placed tadalafil, vardenafil, sildenafil, and avanafil in statistically overlapping confidence intervals for IIEF-EF improvement, with mean differences between active agents of less than 1.5 IIEF points. [12] That gap is below the minimally clinically important difference of 2 to 3 IIEF-EF points established in validation work. [13]

Diabetic Subgroups

Men with type 2 diabetes have reduced NO-mediated signaling and often respond less robustly to all PDE5 inhibitors. Both agents have been studied in diabetic populations. Tadalafil 20 mg on-demand produced a 4.9-point IIEF-EF improvement in a dedicated diabetic trial vs. 0.9 points placebo. [14] Vardenafil 10 mg and 20 mg improved IIEF-EF by 4.2 and 6.5 points respectively in a comparably sized diabetic cohort. [15] Neither drug has proven superiority over the other in this subgroup.

Safety Profile and Side Effects

Shared Adverse Events

Both drugs produce adverse events consistent with systemic vasodilation: headache (10 to 15 percent of patients), facial flushing (11 to 12 percent), nasal congestion (4 to 9 percent), and dyspepsia (3 to 6 percent) at approved on-demand doses. [1][2] Rates are dose-dependent. Back pain and myalgia are more common with tadalafil than vardenafil, occurring in 3 to 6 percent of tadalafil users, likely linked to PDE11 inhibition in skeletal muscle. [4]

Cardiovascular Considerations

Both drugs lower systolic blood pressure by 5 to 8 mmHg on average in healthy volunteers. [16] The combination with alpha-blockers (tamsulosin, doxazosin) produces additive hypotension; the prescribing labels recommend starting with the lowest PDE5 dose and separating administration times by at least 4 hours where possible. [1][2] Nitrates remain an absolute contraindication for both agents. Men who use short-acting nitrates for angina must wait a minimum of 48 hours after their last PDE5 dose before taking nitroglycerin. [17]

A 2014 cardiovascular outcomes analysis in JAMA found no excess cardiovascular event rate attributable to PDE5 inhibitors as a class when prescribed to men without active nitrate use. [18] Princeton Consensus III guidelines (2012) support PDE5 inhibitor use in men categorized as low or intermediate cardiac risk after a structured sexual activity assessment. [17]

QTc Prolongation: Vardenafil's Unique Signal

The vardenafil prescribing label carries a specific warning about QTc prolongation not shared by tadalafil at approved doses. In a thorough QT study, vardenafil 10 mg prolonged the mean QTc interval by 8 milliseconds; the 80 mg supratherapeutic dose prolonged QTc by 10 milliseconds. [2] Clinicians prescribing vardenafil to men on Class Ia antiarrhythmics (quinidine, procainamide) or Class III agents (amiodarone, sotalol) should perform a baseline ECG and re-evaluate the risk-benefit balance. Tadalafil does not carry a QTc label warning at therapeutic doses. [1]

Drug Interactions via CYP3A4

Both tadalafil and vardenafil are metabolized primarily by CYP3A4. Potent CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) substantially raise plasma concentrations of both drugs. [1][2] The tadalafil label recommends a maximum single dose of 10 mg no more than once every 72 hours when co-administered with potent CYP3A4 inhibitors. [1] For vardenafil, the label restricts dosing to 2.5 mg per 24 hours with ritonavir. [2] Rifampin, a potent CYP3A4 inducer, reduces vardenafil AUC by approximately 90 percent, rendering the drug essentially ineffective. [2]

Patient Preference and Real-World Adherence

Real-world adherence data favor the agents that fit a patient's lifestyle rather than those with marginally higher trial efficacy scores. A 2009 preference study (N = 601) that crossed patients over between tadalafil and sildenafil found that 67 percent preferred tadalafil, citing spontaneity as the primary driver. [19] Vardenafil preference studies vs. Tadalafil are less common in the literature, but a cross-over survey published in the International Journal of Clinical Practice (N = 219) found that men with shift-work schedules or irregular sexual frequency preferred vardenafil's shorter window because it produced less concern about prolonged hypotensive effects during overnight work shifts. [20]

The HealthRX Clinical Decision Framework for PDE5 Inhibitor Selection

Consider tadalafil first when:

• The patient wants daily dosing to eliminate timing pressure
• He also has lower urinary tract symptoms from BPH (5 mg daily covers both indications)
• He takes alpha-blockers (the longer half-life allows a stable, predictable interaction profile with appropriate dose separation)
• He does not use antiarrhythmics that prolong QTc

Consider vardenafil first when:

• The patient prefers on-demand dosing with a predictable, short window
• He wants the ODT option (Staxyn) for discreet or waterless administration
• He experienced significant back pain or myalgia on tadalafil
• He reported visual disturbances on sildenafil and wants a PDE6-sparing alternative with a shorter window than tadalafil

Neither agent is preferred when the patient uses organic nitrates. The only option in that scenario is to refer back to cardiology to discuss nitrate substitution or to discuss non-pharmacologic approaches. [17]

Switching From Cialis to Vardenafil (or the Reverse)

Reasons Patients Switch

The most common reasons men switch from tadalafil to vardenafil in clinical practice include persistent back pain or myalgia (3 to 6 percent of tadalafil users), new initiation of a QTc-neutral antiarrhythmic that is nonetheless prescribed by a cautious cardiologist, or partner preference for a tighter timing window. [4][10]

Men switching from vardenafil to tadalafil most often cite scheduling unpredictability, a desire to avoid food restrictions, or interest in daily dosing for concurrent BPH symptom management. [7]

How to Make the Switch Safely

No pharmacokinetic interaction prevents same-day switching, but clinical convention is to wait until the prior dose has cleared (24 hours for vardenafil, 48 hours for tadalafil) before taking the first dose of the new agent. This conservative interval avoids any theoretical additive vasodilation. The starting dose for the new drug should be the lowest approved on-demand dose: 10 mg for both tadalafil and vardenafil. [1][2]

Dose Titration After Switching

Roughly 30 percent of men who respond poorly to one PDE5 inhibitor respond to a second agent from the same class, according to a re-challenge analysis published in the Journal of Sexual Medicine. [21] The mechanism is not fully understood but may involve differences in individual CYP3A4 activity, local PDE5 expression, or placebo-expectancy shifts. A 4-week titration trial at the maximum approved dose is standard before concluding non-response. [13]

Special Populations

Men With Spinal Cord Injury

Both tadalafil and vardenafil have been studied in men with neurogenic ED from spinal cord injury. A randomized trial (N = 418) showed tadalafil 10 and 20 mg produced IIEF-EF improvements of 5.4 and 7.6 points respectively above placebo. [22] Vardenafil produced a 5.7-point improvement in a neurogenic ED subgroup analysis. [15] Tadalafil's longer duration may suit men with spinal cord injury who have limited mobility and less control over the timing of sexual activity.

Older Men (Age 65 and Above)

Renal and hepatic clearance decline with age, raising plasma concentrations of both drugs. The tadalafil label recommends starting at 5 mg for on-demand dosing in men over 65 years. [1] Vardenafil's label recommends starting at 5 mg in this group as well. [2] The cardiovascular risk stratification framework from Princeton Consensus III applies with particular care in this population: exercise tolerance testing is advisable before prescribing in men who cannot achieve 4 METs of exertion. [17]

Post-Radical Prostatectomy

Penile rehabilitation after radical prostatectomy has been studied with both agents. A meta-analysis of 9 randomized trials found that regular PDE5 inhibitor use after nerve-sparing prostatectomy improved recovery of natural erections by 18 percentage points vs. Placebo at 12 to 18 months, regardless of which PDE5 inhibitor was used. [23] The American Urological Association guideline on post-prostatectomy ED does not specify one PDE5 inhibitor over another for rehabilitation. [24]

Cost and Generic Availability

Generic tadalafil became widely available in the United States after patent expiration in 2018. Retail prices for generic tadalafil 20 mg tablets range from approximately $1 to $4 per tablet at major pharmacy chains without insurance, compared with brand-name Cialis prices that exceeded $50 per tablet at peak market exclusivity. [25]

Generic vardenafil has been available since 2018 as well. Retail prices are similar to generic tadalafil at roughly $2 to $5 per tablet for the 20 mg dose. [25] The Staxyn ODT formulation remains more expensive because it is not yet available in a widely distributed generic form in all markets. Patients who prefer the ODT should check with their pharmacy for current generic availability.